Stock Events

Stock Events

COSCIENS Biopharma 

$5.29
76
+$0.34+6.87% Monday 19:12

Statistics

Day High
3.04
Day Low
2.3
52W High
9.5
52W Low
0.79
Volume
2,278
Avg. Volume
2,438
Mkt Cap
16.84M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

13AugExpected
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Q1 2026
Next
-10.44
-5.99
-1.55
2.9
Expected EPS
N/A
Actual EPS
N/A

Financials

-138.14%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
7.5MRevenue
-10.36MNet Income

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
AMGEN
AMGN
Mkt Cap196.12B
Amgen is a biotechnology company that competes in the development of treatments in areas similar to Aeterna Zentaris, including oncology and endocrinology.
Pfizer
PFE
Mkt Cap137.76B
Pfizer is a global pharmaceutical company with a broad product portfolio that includes drugs in areas competing with Aeterna Zentaris' focus, such as cancer and endocrine disorders.
Novo Nordisk
NVO
Mkt Cap218.94B
Novo Nordisk specializes in diabetes care and hormone replacement therapies, directly competing with Aeterna Zentaris' work in endocrinology.
Merck
MRK
Mkt Cap305.12B
Merck is a global healthcare company that develops medicines and vaccines for many of the same diseases Aeterna Zentaris targets, including cancer.
Lilly(Eli) &
LLY
Mkt Cap1.06T
Eli Lilly is a company that focuses on pharmaceuticals in areas like endocrinology and oncology, making it a direct competitor to Aeterna Zentaris.
Abbvie
ABBV
Mkt Cap438.31B
AbbVie operates in the pharmaceutical industry, focusing on treatments for conditions that overlap with Aeterna Zentaris' interests, including hormonal therapies and cancer.
Gilead Sciences
GILD
Mkt Cap161.19B
Gilead Sciences is involved in the discovery, development, and commercialization of innovative therapeutics in areas of unmet medical need, competing with Aeterna Zentaris in the oncology and endocrinology sectors.
Bristol-Myers Squibb
BMY
Mkt Cap117.58B
Bristol Myers Squibb is a global biopharmaceutical company whose range of products in oncology and cardiovascular diseases competes with Aeterna Zentaris.
Sanofi
SNY
Mkt Cap104.13B
Sanofi is a diversified global healthcare leader that develops medications in several areas, including those that compete with Aeterna Zentaris' focus areas.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap38.37B
Teva Pharmaceutical Industries is a global leader in generic and specialty medicines, competing in the pharmaceutical space with a focus on generic versions of drugs that could compete with Aeterna Zentaris' products.

About

COSCIENS Biopharma Inc., a life science company, develops and commercializes products for the cosmeceutical, nutraceutical and pharmaceutical markets in the United States, Germany, the United Kingdom, and internationally. It operates through Active Ingredient and Pharmaceutical segments. The company offers active ingredients comprising oat beta glucan, a functional ingredient that supports overall health and wellness; oat powder and peptides; oat oil which is extracted from whole oat kernels by a gentle process that retains all the important biologically active components; and avenanthramides, a natural-based ingredients used to inflammation-based diseases for the cosmeceutical and pharmaceutical industries. It also provides Macrilen/Ghryvelin (macimorelin), an orally active peptidomimetic small molecule that stimulates the secretion of growth hormone from the pituitary gland. The company sells its products through its distribution network. It has license agreements with Pharmanovia, Davimed GmbH, and NK MEDITECH Ltd, as well as Agriculture Canada, Canadian Government, and University of Alberta. The company was formerly known as Aeterna Zentaris Inc. and changed its name to COSCIENS Biopharma Inc. in August 2024. COSCIENS Biopharma Inc. was incorporated in 1990 and is based in Toronto, Canada.
Show more...
CEO
Mr. Peter Harry Puccetti CFA
Employees
28
Country
Canada
ISIN
CA22112H2000

Listings

MU
DE
ET82.MU
F
DE
ET80.F
XNAS
US
CSCI
MU
DE
ET80.MU

0 Comments

Share your thoughts

FAQ

What is COSCIENS Biopharma stock price today?▼
The current price of CSCIF is $5.29 USD — it has increased by +6.87% in the past 24 hours. Watch COSCIENS Biopharma stock price performance more closely on the chart.
What is COSCIENS Biopharma stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange COSCIENS Biopharma stocks are traded under the ticker CSCIF.
Is COSCIENS Biopharma stock price growing?▼
CSCIF stock has fallen by -6.06% compared to the previous week, the month change is a -8% fall, over the last year COSCIENS Biopharma has showed a -99.67% decrease.
What is COSCIENS Biopharma market cap?▼
Today COSCIENS Biopharma has the market capitalization of 16.84M
When is the next COSCIENS Biopharma earnings date?▼
COSCIENS Biopharma is going to release the next earnings report on August 13, 2026.
What were COSCIENS Biopharma earnings last quarter?▼
CSCIF earnings for the last quarter are 2.9 USD per share, whereas the estimation was N/A USD resulting in a N/A surprise. The estimated earnings for the next quarter are N/A USD per share.
What is COSCIENS Biopharma revenue for the last year?▼
COSCIENS Biopharma revenue for the last year amounts to 7.5M USD.
What is COSCIENS Biopharma net income for the last year?▼
CSCIF net income for the last year is -10.36M USD.
How many employees does COSCIENS Biopharma have?▼
As of August 11, 2026, the company has 28 employees.
In which sector is COSCIENS Biopharma located?▼
COSCIENS Biopharma operates in the Other sector.
When did COSCIENS Biopharma complete a stock split?▼
The last stock split for COSCIENS Biopharma was on July 07, 2026 with a ratio of 1:150.
Where is COSCIENS Biopharma headquartered?▼
COSCIENS Biopharma is headquartered in Toronto, Canada.